{"id":17159,"date":"2021-02-01T14:09:57","date_gmt":"2021-02-01T06:09:57","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=17159"},"modified":"2021-02-01T14:09:58","modified_gmt":"2021-02-01T06:09:58","slug":"snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/","title":{"rendered":"Snapshot week 5\/2021<br>Treatment of a TBE patient with an antiviral drug"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Bologheanu et al.<br>Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravir<br><em>Antiviral Res<\/em>. 2020; 184:104952, doi.org\/10.1016\/j.antiviral.2020.104952<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This publication is dealing with antiviral treatment of a TBE patient with a non-licensed drug.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A 22-year-old male suffered from severe TBE despite primary immunization and regularly administered booster vaccinations. Empirical therapy with acyclovir and ceftriaxone, and symptomatic treatment were initiated. However, during the next few days, the patient became unresponsive and was transferred, already endotracheal intubated, to an intensive care unit. Based on the clinical presentation, West Nile virus (WNV) infection was suspected and treatment with favipiravir was initiated, which has demonstrated efficacy against WNV infection in rodents. The patient received 1600 mg favipiravir twice a day, followed by 600 mg twice daily for seven days. Then, demonstration of IgM and IgG, specific for TBE virus in CSF, was detected and WNV infection was excluded, and therapy with favipiravir was continued. On day 7 of antiviral treatment, almost complete resolution of signal abnormalities was observed. By discharge 14 days after symptom onset, the patient had completely recovered.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Interpretation of the antiviral capacity of favipiravir for therapy of TBE is difficult. Yet, favipiravir is a potent inhibitor of the RNA-dependent RNA polymerase and its efficacy against other flaviviruses has been proven.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Further clinical research on anti TBE virus compounds is warranted.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Some drugs which are FDA approved for antiviral treatment, also show anti-flavivirus specific activity or even anti-TBE virus activity (see Snapshot <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-22-2020evaluation-of-fda-approved-drugs-to-inhibit-flavivirus-replication\/\">week 22\/2020<\/a>). Recently, novel anti TBE virus uridine glycoconjugates have been tested, which look promising in in-vitro anti-TBE virus tests (Brzuska et al, <em>Pharmaceuticals<\/em>. 2020; 13:460, doi:10.3390\/ph13120460).<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Bologheanu et al.Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravirAntiviral Res. 2020; 184:104952, doi.org\/10.1016\/j.antiviral.2020.104952 This publication is dealing with antiviral treatment of a TBE patient with a non-licensed drug. A 22-year-old male suffered from severe TBE despite primary immunization and regularly administered booster vaccinations. Empirical therapy with acyclovir and ceftriaxone, and symptomatic treatment were initiated. However, during the next few days, the patient became unresponsive and was transferred, already endotracheal intubated, to an intensive care unit. Based on the clinical presentation, West Nile virus (WNV) infection was suspected and treatment with favipiravir was initiated, which has demonstrated efficacy against WNV infection in rodents. The patient received 1600 mg favipiravir twice a day, followed by 600 mg twice daily for seven days. Then, demonstration of IgM and IgG, specific for TBE virus in CSF, was detected and WNV infection was excluded, and therapy with favipiravir was continued. On day 7 of antiviral treatment, almost complete resolution of signal abnormalities was observed. By discharge 14 days after symptom onset, the patient had completely recovered. Interpretation of the antiviral capacity of favipiravir for therapy of TBE is difficult. Yet, favipiravir is a potent inhibitor of the RNA-dependent RNA polymerase and its efficacy against other flaviviruses has been proven. Further clinical research on anti TBE virus compounds is warranted. Some drugs which are FDA approved for antiviral treatment, also show anti-flavivirus specific activity or even anti-TBE virus activity (see Snapshot week 22\/2020). Recently, novel anti TBE virus uridine glycoconjugates have been tested, which look promising in in-vitro anti-TBE virus tests (Brzuska et al, Pharmaceuticals. 2020; 13:460, doi:10.3390\/ph13120460).<\/p>\n","protected":false},"author":1354,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[612,613,245,611],"coauthors":[81],"class_list":["post-17159","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-antiviral-treatment","tag-favipiravir","tag-flaviviruses","tag-tbe-vaccine-failure"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 5\/2021Treatment of a TBE patient with an antiviral drug - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 5\/2021Treatment of a TBE patient with an antiviral drug - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Bologheanu et al.Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravirAntiviral Res. 2020; 184:104952, doi.org\/10.1016\/j.antiviral.2020.104952 This publication is dealing with antiviral treatment of a TBE patient with a non-licensed drug. A 22-year-old male suffered from severe TBE despite primary immunization and regularly administered booster vaccinations. Empirical therapy with acyclovir and ceftriaxone, and symptomatic treatment were initiated. However, during the next few days, the patient became unresponsive and was transferred, already endotracheal intubated, to an intensive care unit. Based on the clinical presentation, West Nile virus (WNV) infection was suspected and treatment with favipiravir was initiated, which has demonstrated efficacy against WNV infection in rodents. The patient received 1600 mg favipiravir twice a day, followed by 600 mg twice daily for seven days. Then, demonstration of IgM and IgG, specific for TBE virus in CSF, was detected and WNV infection was excluded, and therapy with favipiravir was continued. On day 7 of antiviral treatment, almost complete resolution of signal abnormalities was observed. By discharge 14 days after symptom onset, the patient had completely recovered. Interpretation of the antiviral capacity of favipiravir for therapy of TBE is difficult. Yet, favipiravir is a potent inhibitor of the RNA-dependent RNA polymerase and its efficacy against other flaviviruses has been proven. Further clinical research on anti TBE virus compounds is warranted. Some drugs which are FDA approved for antiviral treatment, also show anti-flavivirus specific activity or even anti-TBE virus activity (see Snapshot week 22\/2020). Recently, novel anti TBE virus uridine glycoconjugates have been tested, which look promising in in-vitro anti-TBE virus tests (Brzuska et al, Pharmaceuticals. 2020; 13:460, doi:10.3390\/ph13120460).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-01T06:09:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-01T06:09:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Br\u00f6ker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Br\u00f6ker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/\"},\"author\":{\"name\":\"Shaqeez\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\"},\"headline\":\"Snapshot week 5\\\/2021 Treatment of a TBE patient with an antiviral drug\",\"datePublished\":\"2021-02-01T06:09:57+00:00\",\"dateModified\":\"2021-02-01T06:09:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/\"},\"wordCount\":276,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"antiviral treatment\",\"favipiravir\",\"flaviviruses\",\"TBE vaccine failure\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/\",\"name\":\"Snapshot week 5\\\/2021 Treatment of a TBE patient with an antiviral drug - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2021-02-01T06:09:57+00:00\",\"dateModified\":\"2021-02-01T06:09:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 5\\\/2021Treatment of a TBE patient with an antiviral drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\",\"name\":\"Shaqeez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"caption\":\"Shaqeez\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/shaqeez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 5\/2021Treatment of a TBE patient with an antiviral drug - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 5\/2021Treatment of a TBE patient with an antiviral drug - TBE Book","og_description":"Bologheanu et al.Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravirAntiviral Res. 2020; 184:104952, doi.org\/10.1016\/j.antiviral.2020.104952 This publication is dealing with antiviral treatment of a TBE patient with a non-licensed drug. A 22-year-old male suffered from severe TBE despite primary immunization and regularly administered booster vaccinations. Empirical therapy with acyclovir and ceftriaxone, and symptomatic treatment were initiated. However, during the next few days, the patient became unresponsive and was transferred, already endotracheal intubated, to an intensive care unit. Based on the clinical presentation, West Nile virus (WNV) infection was suspected and treatment with favipiravir was initiated, which has demonstrated efficacy against WNV infection in rodents. The patient received 1600 mg favipiravir twice a day, followed by 600 mg twice daily for seven days. Then, demonstration of IgM and IgG, specific for TBE virus in CSF, was detected and WNV infection was excluded, and therapy with favipiravir was continued. On day 7 of antiviral treatment, almost complete resolution of signal abnormalities was observed. By discharge 14 days after symptom onset, the patient had completely recovered. Interpretation of the antiviral capacity of favipiravir for therapy of TBE is difficult. Yet, favipiravir is a potent inhibitor of the RNA-dependent RNA polymerase and its efficacy against other flaviviruses has been proven. Further clinical research on anti TBE virus compounds is warranted. Some drugs which are FDA approved for antiviral treatment, also show anti-flavivirus specific activity or even anti-TBE virus activity (see Snapshot week 22\/2020). Recently, novel anti TBE virus uridine glycoconjugates have been tested, which look promising in in-vitro anti-TBE virus tests (Brzuska et al, Pharmaceuticals. 2020; 13:460, doi:10.3390\/ph13120460).","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/","og_site_name":"TBE Book","article_published_time":"2021-02-01T06:09:57+00:00","article_modified_time":"2021-02-01T06:09:58+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Br\u00f6ker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Br\u00f6ker","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/"},"author":{"name":"Shaqeez","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224"},"headline":"Snapshot week 5\/2021 Treatment of a TBE patient with an antiviral drug","datePublished":"2021-02-01T06:09:57+00:00","dateModified":"2021-02-01T06:09:58+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/"},"wordCount":276,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["antiviral treatment","favipiravir","flaviviruses","TBE vaccine failure"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/","name":"Snapshot week 5\/2021 Treatment of a TBE patient with an antiviral drug - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2021-02-01T06:09:57+00:00","dateModified":"2021-02-01T06:09:58+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 5\/2021Treatment of a TBE patient with an antiviral drug"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224","name":"Shaqeez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d","url":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","caption":"Shaqeez"},"url":"https:\/\/tbenews.com\/tbe\/author\/shaqeez\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1354"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=17159"}],"version-history":[{"count":1,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17159\/revisions"}],"predecessor-version":[{"id":17160,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17159\/revisions\/17160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=17159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=17159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=17159"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=17159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}